SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA. A live webcast of the presentation will be accessible through the Events ...

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has regained compliance with the Nasdaq Stock Market (Nasdaq) continued listing standard for minimum share price under Rule 5450(a)(1) of the Nasdaq Listing Qualifications. On December 17, 2025, the Company received confirmation from the Listing Qualifications ...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on December 15, 2025, the Compensation Committee of Sutro’s Board of Directors granted stock options to purchase 24,500 shares of Sutro common stock and 2,000 restricted stock units (RSUs) to new non-executive employees. The grants were made as an inducement ...

Sutro Biopharma FY Conference Summary Company Overview - **Company**: Sutro Biopharma (NasdaqGM:STRO) - **Focus**: Development of next-generation antibodies using the ExpressCF cell-free platform - **Recent Developments**: Plans to file three Investigational New Drug (IND) applications over the next three years, with one already filed for STRO-004, a tissue factor antibody-drug conjugate (ADC) currently in clinical trials [1][2] Key Points and Arguments Platform and Technology - **ExpressCF Platform**: Enables the production of ADCs with drug exposure two to three times higher than conventional ADCs by optimizing components such as the antibody, linker, and payload [4] - **Site-Specific Conjugation**: Utilizes non-natural amino acids for improved performance and safety of ADCs [4][10] Pipeline and Clinical Trials - **STRO-004**: - Currently in Phase 1 clinical trials, designed to target tissue factor with a focus on safety and efficacy [8][10] - Features a DAR8 exatecan payload, showing enhanced anti-tumor activity at lower doses compared to DAR4 [9] - High non-severely toxic dose (HNSTD) of 50 mg/kg, indicating a strong safety profile [10] - Enrollment for the trial is progressing rapidly, with expectations for top-line data by mid-next year [15] Market Opportunities - **Expansion Beyond Cervical Cancer**: While STRO-004 is initially targeting cervical cancer, there are plans to explore its efficacy in other cancers such as pancreatic, lung, head and neck, and colorectal [19] - **Integrin Beta-6 ADC (STRO-006)**: Targeting a validated cancer marker with plans for IND submission next year [22][24] Dual Payload ADCs - **Innovative Approach**: Combines two different cytotoxic payloads to enhance efficacy and potentially reduce toxicity, addressing resistance issues seen in single-agent therapies [25][30] - **STRO-227**: Targets PTK7, with a focus on cancer stem cells, aiming for a best-in-class profile [27][29] Collaborations and Partnerships - **Astellas Partnership**: Developing immunostimulatory ADCs that combine cytotoxic agents with immune-activating components, expected to enter clinical trials early next year [33] Financial Position - **Cash Runway**: Ended Q3 with approximately $168 million, extending the runway into mid-2027, allowing for further program validation and potential business development opportunities [34][35] Additional Insights - **Clinical Relationships**: Emphasis on building strong relationships with investigators to facilitate rapid enrollment and execution of clinical trials [13][17] - **Transformative Year**: 2025 marked a significant transformation for Sutro, with a return to clinical trials and multiple programs expected to enter the clinic next year [35] This summary encapsulates the critical developments and strategic direction of Sutro Biopharma, highlighting its innovative approaches in the ADC space and the potential for significant market impact.

Core Insights - Sutro Biopharma has initiated dosing in its Phase 1 trial for STRO-004, an antibody-drug conjugate targeting Tissue Factor (TF) in solid tumors, marking a significant milestone in oncology treatment options [2][3] - The trial aims to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004, with initial clinical data expected by mid-2026 [1][3] Company Overview - Sutro Biopharma is a clinical-stage oncology company focused on developing site-specific and novel-format antibody-drug conjugates (ADCs) [2][6] - The company utilizes a proprietary cell-free platform to engineer ADCs, enhancing stability, potency, and tumor selectivity [2][5] Product Details - STRO-004 is designed to deliver potent anti-tumor activity with a drug-to-antibody ratio of 8 (DAR8), featuring a high-affinity antibody and a cleavable linker [5] - Preclinical studies have shown STRO-004 to have robust anti-tumor activity and favorable tolerability compared to existing therapies [5] Clinical Trial Information - The Phase 1 trial is open-label and multicenter, targeting advanced TF-expressing solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma [3][5] - The trial includes a dose-escalation phase with multiple cohorts, aiming to identify a recommended Phase 2 dose quickly [3]

Core Points - Sutro Biopharma, Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-10, effective December 3, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 85,193,912 to about 8,519,392 [2] - Proportionate adjustments will be made to the exercise prices and number of shares underlying the Company's outstanding equity awards and incentive plans [2] - No fractional shares will be issued; stockholders entitled to fractional shares will receive shares rounded up to the nearest whole share [3] Group 2: Company Overview - Sutro Biopharma is focused on developing next-generation antibody-drug conjugates (ADCs) aimed at improving cancer treatment [4] - The Company utilizes a cell-free platform to produce ADCs that enhance drug exposure, minimize side effects, and target a broader range of tumor types [4] - Sutro's pipeline includes single- and dual-payload ADCs targeting large oncology markets with significant unmet needs [4]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - Sutro is focusing on a new strategy aimed at enhancing its differentiated pipeline of antibody-drug conjugates (ADCs) [1][2] - The company is executing this strategy with a new leadership team and aims to deliver results rapidly [2] - Sutro's ADC technology is positioned to create a significant impact in cancer treatment, with ambitions to lead the future of the ADC field [2] Company Strategy - The new strategy emphasizes the scientific foundation behind Sutro's platform and the potential of its ADC pipeline [1] - There is strong conviction in the differentiated nature of the pipeline based on emerging scientific data [1] Execution and Leadership - The company has a new leadership team that is focused on executing the new strategy effectively and swiftly [2] - The emphasis is on driving value for patients and stakeholders in the coming years [2] Future Outlook - Sutro aims to not only participate in the ADC market but to define its future trajectory [2] - The presentation highlights the potential of the ADC technology to change the landscape of cancer therapies [2]

Sutro Biopharma 2025 R&D Day Summary Company Overview - **Company**: Sutro Biopharma (NasdaqGM:STRO) - **Focus**: Development of differentiated antibody-drug conjugates (ADCs) for cancer treatment Key Industry Insights - **ADC Field**: Sutro aims to not only participate but to define the future of the ADC field, leveraging its unique technology to create highly differentiated therapies [4][6][9] - **Market Need**: There is a significant unmet need for better cancer treatments, particularly for patients who have relapsed after standard therapies, with nearly 500,000 patients annually in the U.S. alone requiring new options [33] Core Points and Arguments 1. **Strategic Reset**: Sutro has undergone a strategic pivot since March, focusing on a new leadership team and an ambitious clinical development plan [6][9] 2. **Pipeline Development**: The company has a robust pipeline including STRO-004 (tissue factor ADC) and STRO-006 (integrin beta-6 ADC), with plans for multiple INDs in the coming years [5][7][12] 3. **Technological Differentiation**: Sutro's ADC technology allows for optimization of every component (antibody, linker, payload), leading to improved safety and efficacy profiles compared to conventional ADCs [10][11][20] 4. **Clinical Progress**: STRO-004 is now active and enrolling, with initial data expected in 2026. The program shows promise in treating multiple solid tumors beyond cervical cancer [13][26] 5. **Dual Payload ADCs**: Sutro is pioneering dual payload ADCs designed to overcome resistance and improve efficacy, with the first program targeting PTK7 expected to enter the clinic in 2026 [15][16][19] 6. **Safety Profile**: Sutro's ADCs, particularly STRO-004, demonstrate a favorable safety profile with a higher maximum tolerated dose (HNSTD) of 50 mg/kg, compared to competitors [21][26] Additional Important Insights - **Leadership and Expertise**: The new senior leadership team brings extensive ADC experience, enhancing Sutro's capability to execute its strategy effectively [8][9] - **Manufacturing Innovations**: Sutro utilizes a cell-free manufacturing platform that allows for rapid optimization and scalability of ADCs, differentiating it from conventional methods [56][60] - **Clinical Validation**: The company emphasizes the importance of clinical validation for its ADCs, with a focus on achieving better pharmacokinetics (PK) and safety profiles [55][59] - **Future Directions**: Sutro is exploring novel payloads and combinations to enhance the therapeutic index of its ADCs, aiming to address the limitations of current therapies [43][51] Conclusion Sutro Biopharma is positioned as a leader in the ADC space with a strong pipeline and innovative technology aimed at transforming cancer treatment. The company's strategic focus on dual payload ADCs and a commitment to safety and efficacy could significantly impact patient outcomes in oncology.

Core Insights - Sutro Biopharma has initiated a Phase 1 study for STRO-004, a potential best-in-class Tissue Factor ADC, marking a significant step in its clinical development [1] - The company has selected PTK7 as the target for its first dual-payload candidate, STRO-227, which aims to address difficult-to-treat solid tumors [1][5] - Sutro is hosting a virtual R&D Day to discuss its innovative ADC platform and pipeline, emphasizing its near- and long-term priorities [1][2] Company Overview - Sutro Biopharma is a clinical-stage oncology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs) [1][8] - The company utilizes a proprietary cell-free platform that allows for optimized design of ADCs, enhancing safety and efficacy [3][8] ADC Pipeline Highlights - **Single-Payload ADC Programs** - STRO-004 has entered clinical trials after receiving IND clearance from the FDA, showing promising anti-tumor activity in preclinical models for various cancers [4] - STRO-006, targeting integrin β6, is expected to enter clinical development in 2026, demonstrating a superior pharmacokinetic profile compared to existing ADCs [4] - **Dual-Payload ADC Program** - STRO-227 targets PTK7, which is overexpressed in several cancers, with an IND submission planned for 2026/2027 [5][11] Strategic Collaborations - Sutro is collaborating with Astellas to advance dual-payload immunostimulatory ADCs, with the first program expected to enter clinical trials in early 2026 [6]